Randomised controlled trials RCTs that compared combination disease modifying antirheumatic drugs DMARDs and or tumour necrosis factor inhibitors methotrexate combination therapy versus methotrexate monotherapy were eligible for inclusion in the review clomid and nolvadex While several reports suggest a number of HDAC inhibitor targets, both histone and non histone, as relevant for their observed anti tumour activity, our preclinical data suggest that the depletion of HDAC2 by siRNA is sufficient, as its depletion mimics the effects of an HDAC inhibitor tamoxifen combination in vitro